FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3215197047> ?p ?o ?g. }

• W3215197047 endingPage "1007" @default.
• W3215197047 startingPage "997" @default.
• W3215197047 abstract "Larotrectinib is a first-in-class, highly selective tropomyosin receptor kinase (TRK) inhibitor approved to treat adult and pediatric patients with TRK fusion-positive cancer. The aim of this study was to evaluate the efficacy and safety of larotrectinib in patients with TRK fusion-positive primary central nervous system (CNS) tumors.Patients with TRK fusion-positive primary CNS tumors from two clinical trials (NCT02637687, NCT02576431) were identified. The primary endpoint was investigator-assessed objective response rate (ORR).As of July 2020, 33 patients with TRK fusion-positive CNS tumors were identified (median age: 8.9 years; range: 1.3-79.0). The most common histologies were high-grade glioma (HGG; n = 19) and low-grade glioma (LGG; n = 8). ORR was 30% (95% confidence interval [CI]: 16-49) for all patients. The 24-week disease control rate was 73% (95% CI: 54-87). Twenty-three of 28 patients (82%) with measurable disease had tumor shrinkage. The 12-month rates for duration of response, progression-free survival, and overall survival were 75% (95% CI: 45-100), 56% (95% CI: 38-74), and 85% (95% CI: 71-99), respectively. Median time to response was 1.9 months (range 1.0-3.8 months). Duration of treatment ranged from 1.2-31.3+ months. Treatment-related adverse events were reported for 20 patients, with grade 3-4 in 3 patients. No new safety signals were identified.In patients with TRK fusion-positive CNS tumors, larotrectinib demonstrated rapid and durable responses, high disease control rate, and a favorable safety profile." @default.
• W3215197047 created "2021-12-06" @default.
• W3215197047 creator A5001066329 @default.
• W3215197047 creator A5005645968 @default.
• W3215197047 creator A5006442132 @default.
• W3215197047 creator A5008878915 @default.
• W3215197047 creator A5011675274 @default.
• W3215197047 creator A5013000361 @default.
• W3215197047 creator A5020352800 @default.
• W3215197047 creator A5024958186 @default.
• W3215197047 creator A5025577967 @default.
• W3215197047 creator A5026095888 @default.
• W3215197047 creator A5027426012 @default.
• W3215197047 creator A5036717623 @default.
• W3215197047 creator A5038338410 @default.
• W3215197047 creator A5046321083 @default.
• W3215197047 creator A5047271752 @default.
• W3215197047 creator A5051922909 @default.
• W3215197047 creator A5054216397 @default.
• W3215197047 creator A5059915005 @default.
• W3215197047 creator A5060949051 @default.
• W3215197047 creator A5061665043 @default.
• W3215197047 creator A5063120070 @default.
• W3215197047 creator A5063199354 @default.
• W3215197047 creator A5068715356 @default.
• W3215197047 creator A5069043826 @default.
• W3215197047 creator A5084340215 @default.
• W3215197047 creator A5086018137 @default.
• W3215197047 creator A5087551014 @default.
• W3215197047 creator A5087839513 @default.
• W3215197047 creator A5090832721 @default.
• W3215197047 creator A5091013379 @default.
• W3215197047 date "2021-11-27" @default.
• W3215197047 modified "2023-10-14" @default.
• W3215197047 title "Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors" @default.
• W3215197047 cites W2016392763 @default.
• W3215197047 cites W2019607817 @default.
• W3215197047 cites W2053343049 @default.
• W3215197047 cites W2053349906 @default.
• W3215197047 cites W2074042694 @default.
• W3215197047 cites W2081975691 @default.
• W3215197047 cites W2109269285 @default.
• W3215197047 cites W2131545168 @default.
• W3215197047 cites W2139565721 @default.
• W3215197047 cites W2149290144 @default.
• W3215197047 cites W2152531047 @default.
• W3215197047 cites W2157226283 @default.
• W3215197047 cites W2162643152 @default.
• W3215197047 cites W2168394700 @default.
• W3215197047 cites W2335155752 @default.
• W3215197047 cites W2417583025 @default.
• W3215197047 cites W2651525809 @default.
• W3215197047 cites W2753017211 @default.
• W3215197047 cites W2787816121 @default.
• W3215197047 cites W2790254562 @default.
• W3215197047 cites W2802365177 @default.
• W3215197047 cites W2888845108 @default.
• W3215197047 cites W2891473286 @default.
• W3215197047 cites W2894551693 @default.
• W3215197047 cites W2896424462 @default.
• W3215197047 cites W2900674461 @default.
• W3215197047 cites W2946636780 @default.
• W3215197047 cites W2947284548 @default.
• W3215197047 cites W2975995592 @default.
• W3215197047 cites W2990614727 @default.
• W3215197047 cites W3001529224 @default.
• W3215197047 cites W3008107700 @default.
• W3215197047 cites W3010860768 @default.
• W3215197047 cites W3013178156 @default.
• W3215197047 cites W3014806119 @default.
• W3215197047 cites W3033591069 @default.
• W3215197047 cites W3042369616 @default.
• W3215197047 cites W3168910047 @default.
• W3215197047 cites W3174246647 @default.
• W3215197047 cites W4233447779 @default.
• W3215197047 doi "https://doi.org/10.1093/neuonc/noab274" @default.
• W3215197047 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34850167" @default.
• W3215197047 hasPublicationYear "2021" @default.
• W3215197047 type Work @default.
• W3215197047 sameAs 3215197047 @default.
• W3215197047 citedByCount "58" @default.
• W3215197047 countsByYear W32151970472022 @default.
• W3215197047 countsByYear W32151970472023 @default.
• W3215197047 crossrefType "journal-article" @default.
• W3215197047 hasAuthorship W3215197047A5001066329 @default.
• W3215197047 hasAuthorship W3215197047A5005645968 @default.
• W3215197047 hasAuthorship W3215197047A5006442132 @default.
• W3215197047 hasAuthorship W3215197047A5008878915 @default.
• W3215197047 hasAuthorship W3215197047A5011675274 @default.
• W3215197047 hasAuthorship W3215197047A5013000361 @default.
• W3215197047 hasAuthorship W3215197047A5020352800 @default.
• W3215197047 hasAuthorship W3215197047A5024958186 @default.
• W3215197047 hasAuthorship W3215197047A5025577967 @default.
• W3215197047 hasAuthorship W3215197047A5026095888 @default.
• W3215197047 hasAuthorship W3215197047A5027426012 @default.
• W3215197047 hasAuthorship W3215197047A5036717623 @default.
• W3215197047 hasAuthorship W3215197047A5038338410 @default.
• W3215197047 hasAuthorship W3215197047A5046321083 @default.

• next